GLPG Multiplikator Forward P/S Galapagos Genomics
The stable operation of Galapagos NV production capacities creates a foundation for growth, which is further strengthened by strategic alliances and the acquisition of biotech startups. This chart of the expected P/S metric from the GURU.Markets terminal shows the current level is around 1.40. This price action confirms a trajectory toward leadership in immunology through the implementation of innovative CAR-T therapy, which reduces treatment delivery times for patients.
Rincian metrik keuangan lan pasar Galapagos NV (GLPG)
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi pasar:
- statistik nilai buku emiten:
- indikator beban kredit lan likuiditas emiten:
Utang marang Ekuitas Galapagos NV|GLPG - Kewajiban jangka dawa marang ekuitas|Utang jangka cendhak marang modal glpg.com|GLPG - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Galapagos NV|GLPG - Tanggungan jangka dawa|Utang jangka cendhak perusahaan Galapagos|Likuiditas cepet glpg.com
- data bathi bisnis lan rasio investasi:
GLPG - Asil keuangan resik|Bathi mangsa ngarep Galapagos NV|GLPG - Nilai perusahaan marang bathi resik|Rega marang bathi mangsa ngarep Galapagos|GLPG - Rasio P/E diaturake wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Galapagos NV|GLPG - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Galapagos|GLPG - Bathi resik saben saham sajroning taun lumaku|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan glpg.com|GLPG - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Galapagos NV
- indikator pendapatan dodolan lan penghasilan bisnis:
Analisis fundamental perusahaan:Galapagos N.V. GLPG
Forward P/S determines the market value of a company relative to expected revenue, calculated as the ratio of current market capitalization to projected sales for a future period. By analyzing the forward P/S ratio, an investor assesses the fairness of the valuation of Galapagos NV (GLPG), where a massive liquidity reserve from partnerships minimizes the risk of cash flow gaps when financing costly R&D projects.
Pesaing utama
Multiplikator Forward P/S HLN (Haleon PLC)|Multiplikator Forward P/S Kenvue Corp KVUE|Verona Pharma PLC - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep jyongbio.com|LGND: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan AMRX|Rasio rega marang prakiraan pendapatan Perrigo Company|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Alvotech ALVO|Multiplikator Forward P/S LQDA|ANIP: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S MNKD (MannKind Corp)|Rasio kapitalisasi marang dodolan sing dikarepake Amphastar (AMPH)|PCRX: Multiplikator forward rega marang pendapatan|SPRY - Multiplikator Forward P/S|Theravance Biopharma, Inc. (TBPH) - Rasio rega marang prakiraan pendapatan|AQST (Aquestive Therapeutics) - Rasio rega marang prakiraan pendapatan|SCPH (scpharmaceuticals.com) - Multiplikator Forward P/S|TECX: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Tonix Pharmaceuticals Inc. (TNXP)|SXTC (SXT Pharmaceuticals) - Rega forward marang dodolan|Multiplikator Forward P/S EPRX (Eupraxia Pharmaceuticals)|Rega forward marang dodolan BHST|Invizyne Technologies - Multiplikator Forward P/S|oramed.com (ORMP) - Multiplikator forward rega marang pendapatan|ENTX (enterabio.com) - Multiplikator forward rega marang pendapatan|Kapitalisasi marang prakiraan pendapatan HYFT|ABVC (ABVC BioPharma, Inc) - Multiplikator Forward P/S|Multiplikator Forward P/S cumberlandpharma.com|Rasio rega marang prakiraan pendapatan Quantum BioPharma (QNTM)|FibroGen (FGEN) - Prakiraan rega marang pendapatan|Multiplikator Forward P/S TELO (telomirpharma.com)|RANI - Multiplikator forward rega marang pendapatan|SNYR - Rasio rega marang prakiraan pendapatan|rallybio.com - Rasio rega marang pendapatan sing dikarepake|LEXX: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Pulmatrix Inc|PTHL (Pheton Holdings) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Aptorum Group Limited APM|Rasio rega marang prakiraan pendapatan Lyra Therapeutics (LYRA)|Multiplikator forward rega marang pendapatan Impact BioMedical Inc IBO|Rasio rega marang prakiraan pendapatan tnfpharma.com TNFA|Rega forward marang dodolan YCBD|PainReform Ltd - Multiplikator Forward P/S|Altamira Therapeutics Ltd (CYTO) - Multiplikator forward rega marang pendapatan|lipella.com (LIPO) - Rasio rega marang prakiraan pendapatan|OptiNose (OPTN) - Multiplikator Forward P/S|PIRS (Pieris Pharmaceuticals Inc) - Multiplikator Forward P/S|PROC: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Petros Pharmaceuticals, Inc. (PTPI)|Multiplikator Forward P/S Qilian International Corp (QLI)|ACELYRIN, Inc. - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S tffpharma.com TFFP
